**POSO379**

**DETERMINING IN WHICH PRECLINICAL STAGE HLA-SHARED EPITOPE ALLELES AND SMOKING EXERT THEIR EFFECT IN THE DEVELOPMENT OF RHEUMATOID ARTHRITIS**

E. Wouters1, M. Maurit2, L. van Boheemen3, M. Versstappen2, X. Matthijssen2, E. Niemantsverdriet2, R. Kneef2, D. van Schaardenburg4, R. Toes3, A. van der Helm - van Mil4,4. *Leiden University Medical Centre, Department of Rheumatology, Leiden, Netherlands; 2Leiden University Medical Centre, Department of Rheumatology, Leiden, Netherlands; 3Amsterdam Rheumatology and Immunology Centre, Reade, Department of Rheumatology, Amsterdam, Netherlands; 4Erasmus University Medical Centre, Department of Rheumatology, Rotterdam, Netherlands*

**Background:** The HLA shared epitope (SE) and smoking are the best known genetic and environmental risk factors for rheumatoid arthritis (RA) development; however, at which pre-RA stage they exert their effect is unknown. The following stages are discerned: an asymptomatic stage in which autoimmune responses can develop, a symptomatic stage (clinically suspect arthralgia (CSA)), and development of clinically apparent inflammatory arthritis (IA). Studies in the general asymptomatic population revealed contrasting results on the associations between SE-alleles and smoking and the presence of anti-citrullinated protein antibodies (ACPA). Furthermore, studies on these risk factors in the symptomatic pre-RA phase are scarce and these data might teach us whether SE-alleles and smoking are involved in symptom development and/or progression to clinical arthritis.

**Objectives:** We aimed to determine at which pre-RA stage SE and smoking exert their effect. In this respect, the analyses were focused on the presence of ACPA, but associations for other anti-modified protein antibodies (anti-carbamylated and anti-acetylated protein antibodies (anti-CarbP and AAPA, respectively)) were also studied.

**Methods:** Results from the literature on the association of SE and smoking with ACPA in the asymptomatic population were summarized in inverse-variance weighted meta-analyses. In addition 577 CSA-patients were studied. Associations of SE and smoking with IgG ACPA were studied at baseline (CSA-onset), to assess an effect on symptom development. Additionally, patients were monitored for the development of clinically apparent inflammatory arthritis (IA) for median 2 years and associations of SE, smoking and auto-antibodies with progression to IA were determined. Analyses were stratified for ACPA-status and associations in ACPA-positive patients were validated in meta-analyses with other arthralgia-cohort studies. Finally analyses were repeated for anti-CarbP and AAPA.

**Results:** Meta-analyses showed that SE is not associated with ACPA-positivity in the asymptomatic population (OR 1.06 (95%CI 0.96-1.16)), whereas smoking was associated (OR 1.17 (1.13-1.63)). At CSA-onset, both SE and smoking associated with ACPA-positivity (OR 2.08 (1.24-3.49) and OR 2.41 (1.31-4.43), respectively). During follow-up of CSA-patients SE associated with IA-development (HR 1.86 (1.23-2.82)), in contrast to smoking. SE conferred risk for IA-development in ACPA-negative CSA-patients (HR 1.71 (0.99-2.96)) and in ACPA-positive patients (CSA-cohort HR 1.29 (0.67-2.47); meta-analysis three arthralgia-cohorts HR 1.52 (1.08-2.15)). Investigating the other autoantibodies revealed that SE and smoking were not associated with anti-CarbP or AAPA-positivity at CSA-onset; longitudinally AAPA associated with progression to IA independent from ACPA and RF (HR 1.79 (1.02-3.16)), whilst anti-Carp did not.

**Conclusion:** SE and smoking act in partly different pre-RA stages. Although SE does not associate with ACPA in the general population, it does mediate symptom-development and further progression to clinical arthritis. Smoking confers risk to development of ACPA and/or joint symptoms, but is not further involved in IA-development. The time-specific biologic pathways that are underlying need further exploration. These data enhance the understanding of the timing of key genetic and environmental risk factors in the trajectory of RA development.

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2021-eular.1342

---

**POSO381**

**PATIENTS AT RISK FOR RA SHOW THE SAME AMOUNT OF ACUTE SOLUBLE CARTILAGE DEGRADATION MARKERS AFTER PHYSICAL ACTIVITY COMPARED TO PATIENTS WITH ESTABLISHED RA**

I. Blochweidel-Rolack1, K. Taschler1, V. Nee1, J. Hühne2, A. Huber2, J. Rech1, G. Schett1, A. Kleyer1, A. M. Liphardt1. 1Friedrich-Alexander-University Erlangen-Nürnberg & University Hospital Erlangen, Internal Medicine 3 - Rheumatology & Immunology, Erlangen, Germany; 2Socialinstitut Bamberg Klinikum am Bruderwald, Rheumatology, Bamberg, Germany

**Background:** Serum concentration of cartilage oligomeric matrix protein (COMP) is related to the degree of cartilage destruction in patients with rheumatoid arthritis (RA) and shows a mechanosensitive response to ambulatory loads. We showed previously, that individuals with positive for anti-citrullinated protein antibody (ACPA+) status already show bone loss. It is unclear if these individuals experience cartilage deterioration and how this is related to physical activity.

**Objectives:** To test whether soluble COMP levels in ACPA+ display the same response as RA patients after a walking exercise and explore the association between overall serum COMP levels and physical activity.

**Methods:** RA patients and ACPA+ individuals (RAE cohort: Individuals at Risk for Arthritis Cohort Erlangen; Ethics approval 334_16B) were enrolled in the study after written informed consent. Inclusion criteria were age between 18 and 69 years, RA (by 2010 ACR/EULAR criteria) or ACPA+ (without clinical manifestation of RA and prior treatment with glucocorticoids, DMARDs and biologics). The study comprised three visits (baseline (Visit 1), 6 (Visit 2), and 12 months (Visit 3)). During each visit, serum samples were collected after 30 minutes rest (pre) and at 0, 30, 60, and 120 minutes after a 30-minute walking exercise. Serum COMP concentration was analyzed by commercial ELISA. Physical activity duration (hours) was measured using an activity monitor for 7 consecutive days, and physical activity level (metabolic equivalent of the task (MET)) was quantified using the International Physical Activity Questionnaire (IPAQ). The reponse of COMP levels to the walking exercise was modelled using linear mixed-effects regression models. The association between physical activity and overall serum factor-X (TNF-α), adiponectin (leptin, adiponectin, resistin) and other newly identified proinflammatory factors (fetuin A, nesfatin, hemerin, lipokain, serum amyloid protein 3) [1,2,3,4].

**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2021-eular.1432

---

**POSO380**

**HORMONES OF ADIPOSE TISSUE IN PATIENTS WITH RHEUMATOID ARTHRITIS WHO HAVE REDUCED BODY WEIGHT**

L. Arefeva1, G. Kravtsov2, V. Polyakov2, V. Kravtsov3, L. Siewerdovs. 1Volgograd State Medical University, Cardiology of University Clinical, Volgograd, Russian Federation; 2Volgograd State Medical University, Cardiology of University Clinical, Volgograd, Russian Federation; 3Volgograd State Medical University, Cardiology of University Clinical, Volgograd, Russian Federation; 4Federal State Budgetary Institution «Zborovsky Research Institute of Clinical and Experimental Rheumatology», Laboratory Methods of Treatment and Prevention of Joint Diseases, Volgograd, Russian Federation

**Background:** Overweight in patients with rheumatic diseases is a condition that prolongs chronic inflammation and promotes synthesis and secretion of pro-inflammatory factors by adipose tissue, such as classical cytokines, tumor necrosis factor-α (TNF-α), adiponectin (leptin, adiponectin, resistin) and other newly identified proinflammatory factors (fetuin A, nesfatin, hemerin, lipokain, serum amyloid protein 3) [1,2,3,4].

**Objectives:** We investigated the relationship of the effect of weight loss over 5kg on the clinical manifestations of arthritis and hormones of adipose tissue serum levels in patients with rheumatoid arthritis (RA).

**Methods:** We observed 80 female patients with RA (EULAR/ARA 2010 criteria) ranged in age from 39 to 69 years (mean age 51.72 ± 5.83 years) and the control group (60 healthy persons) with no complaints of pain in the joints over a lifetime, and without clinical signs of RA. Fetuin A, nesfatin, hemerin, leptin, adiponectin, resistin, visfatin level in serum was determined by ELISA test using a commercial test systems.

**Results:** As overweight patients were recruited in the study, hydropic diet low in animal fats and phytotherapy has been recommended to all participants. The positive dynamics in body weight loss over 5kg within 3 months has been achieved by 34 patients (22.72%). In RA patients with weight loss, a significant decrease in the serum level of pro-inflammatory cytokines (fetuin A, nesfatin, hemerin, leptin, adiponectin, resistin, visfatin (p<0.01)) and an increase in the quality of life according to the EQ-5D-5L (<0.01) index were observed. This fact is probably explained by the decreased activity of inflammatory process after RA therapy and weight reduction.

**Conclusion:** Thus, as a result of our study patients with RA with weight loss of more than 5kg had more obvious pain relief than patients with the original weight. These findings suggest that there is a possible role of tissue pro-inflammatory cytokines in the pathogenesis of rheumatoid arthritis. All patients with RA with a BMI over 25 kg/m² are recommended to lower their weight to decrease the mechanical stress on the joints, and also to reduce the severity of inflammation and metabolic disorders.

**REFERENCES:**


**Disclosure of Interests:** None declared.

**DOI:** 10.1136/annrheumdis-2021-eular.1432
COMP concentrations was analyzed using a mixed-effects regression model (Random effects: individuals, visits and COMP measurement time points).

**Results:** 28 RA and 22 ACPA+ patients participated in this prospective study. Serum COMP levels increased in response to the walking exercise in both groups but the acute response was not different in RA patients compared to ACPA+ individuals. Higher physical activity level by IPAQ was associated with higher overall COMP concentration. Doubling of total physical activity is associated with an increase in serum concentration of 0.32 U/L (95%CI 0.09 to 0.54, p=0.006). ACPA+ individuals but not RA patients show an association between serum COMP concentration and physical activity duration (Figure 1).

Table 1. Summary of subject characteristics and outcome measures.

<table>
<thead>
<tr>
<th>Measure</th>
<th>ACPA+</th>
<th>RA</th>
</tr>
</thead>
<tbody>
<tr>
<td>individuals, number (%)</td>
<td>22 (44.0)</td>
<td>28 (56.0)</td>
</tr>
<tr>
<td>Age, years (mean (SD))</td>
<td>47.6 (12.8)</td>
<td>57.0 (9.1)</td>
</tr>
<tr>
<td>Female, number (%)</td>
<td>14 (28.0)</td>
<td>19 (38.0)</td>
</tr>
<tr>
<td>BMI, kg/m², mean (SD)</td>
<td>25.1 (5.6)</td>
<td>27.2 (5.8)</td>
</tr>
<tr>
<td>Anti-CPP positive (N)</td>
<td>17</td>
<td>14</td>
</tr>
<tr>
<td>DAS28-score, mean (SD)</td>
<td>2.5 (1.2)</td>
<td>2.7 (1.4)</td>
</tr>
</tbody>
</table>

Table 1. Summary of subject characteristics and outcome measures.

Figure 1. Estimated marginal mean COMP by physical activity duration for RA and ACPA+.

**Conclusion:** Pre-exercise serum COMP concentration is similar in ACPA+ and RA and shows a similar increase in response to walking in both groups. Physical activity duration appears to influence serum COMP concentration in ACPA+. Given that acute COMP release was not different between ACPA+ and RA while overall COMP values are associated with physical activity level, the discrepancy between ACPA+ and RA for this association can be explained by reduced vigor or qualitative differences in physical activity.

**Disclosure of Interests:** Lisa Bleckwedel-Rolack: None declared, Koray Tasiller: None declared, Julia Hühne: None declared, Axel Hueber: None declared, Jürgen Rech Speakers bureau: Abbvie, Biogen, BMS, Chugai, GSK, Lilly, MSD; Mylan, Novartis, Roche, Sanofi, Sobi, UCB, Consultant of: Abbvie, Biogen, BMS, Chugai, GSK, Lilly, MSD; Mylan, Novartis, Roche, Sanofi, Sobi, UCB, Grant/research support from: Novartis, Sobi, Georg Schett Speakers bureau: Lilly, Novartis, Consultant of: Lilly, Novartis, Gilead, BMS, Abbvie, Grant/research support from: Novartis, Sobi, UCB, Consultant of: Lilly, Novartis, Gilead, BMS, Abbvie, Grant/research support from: Lilly, Novartis, Anna-Maria Liphardt Speakers bureau: Mylan, Paid instructor for: Abby, Consultant of: Abbvie, Consultant of: MDA Pharma, Grant/research support from: Novartis

**DOI:** 10.1136/annrheumdis-2021-eular.1527

**POS0382**

EXPANSION OF CD4+/CD8+ DOUBLE-POSITIVE T CELLS IS ASSOCIATED WITH A SEVERE DISEASE COURSE IN RHEUMATOID ARTHRITIS

P. Nguyen1, K. Rothe1, M. Melzer1, M. Krasselt1, M. Priefer1, U. Wagner1.

1Leipzig University Hospital, Rheumatology, Leipzig, Germany

**Background:** CD4+/CD8+ double-positive T (dpT) cells are a set of pathologic T cells, representing about 1% of peripheral blood T cells and increasing with age in healthy individuals. Patients with rheumatoid arthritis (RA) more frequently have expanded dpT cells compared to age-matched controls, up to a frequency of 8% [1]. However, whether dpT cell expansion harbors clinical significance in RA is not known.

**Objectives:** The goal of the study was to assess possible associations of dpT expansion with clinical features of patients with RA.

**Methods:** In this cross-sectional study, dpT cells were measured in RA patients (n=70) via fluorescence-activated flow cytometry. Clinical data including age, sex, disease duration, treatment history, disease activity parameters, and radiographic structural damage was collected. Radiographs of hands and feet were used to determine the modified Sharp/van der Heijde (SvdH) score. Expansion of dpT cells was defined as a frequency of >2% of the total T cell pool, based on range references determined in a large cohort of healthy individuals [2]. Mann-Whitney-U test was used to compare groups and X² test was used for contingency tables. Statistical analyses were conducted using GraphPad Prism v8 (GraphPad Software, San Diego, USA).

**Results:** DpT cells were expanded in more than a quarter of our cohort (n=19, 27.1%). Patients with expanded dpT cells more often used biologics or targeted synthetic DMARDs than patients with low dpT cells (68.4% vs. 38%, p=0.02). Radiographic damage was also significantly worse in patients with DPT expansion, as shown in their higher SvdH score (median 24.5 vs. 6, p=0.008) and its component scores for erosion (median 19 vs. 0, p=0.004) and joint space narrowing (median 8 vs. 2, p=0.017) (figure 1A). There was no difference regarding sex, age, disease duration, seropositivity and disease activity between the groups (figure 1B).

**Conclusion:** DpT cell expansion is associated with higher scores of radiographic structural damage despite more frequent use of highly effective therapeutics. An expansion of dpT cells is not uncommon in RA, and affected patients represent a subset at high risk for a more severe disease course.

**REFERENCES:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2021-eular.1533